Search Results - Andrea Terret

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    A GIS-based multiscale mapping framework to assess and visualize complex and polygenetic geomorphic systems – A novel ‘Geomorphic Entities’ approach

    A GIS-based multiscale mapping framework to assess and visualize complex and polygenetic geomorphic systems – A novel ‘Geomorphic Entities’ approach by Manuel La Licata, Alberto Bosino, Mattia De Amicis, Andrea Terret, Michael Maerker

    Published in Journal of maps
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    The SIOD disorder protein SMARCAL1 is an RPA-interacting protein involved in replication fork restart

    The SIOD disorder protein SMARCAL1 is an RPA-interacting protein involved in replication fork restart by Ciccia, Alberto, Bredemeyer, Andrea L, Sowa, Mathew E, Terret, Marie-Emilie, Jallepalli, Prasad V, Harper, J Wade, Elledge, Stephen J

    Published in Genes & development
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study

    Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer... by Angevin, Eric, Cassier, Philippe A., Italiano, Antoine, Gonçalves, Anthony, Gazzah, Anas, Terret, Catherine, Toulmonde, Maud, Gravis, Gwenaëlle, Varga, Andrea, Parlavecchio, Cédric, Paci, Angelo, Poinsignon, Vianney, Soria, Jean-Charles, Drubay, Damien, Hollebecque, Antoine

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    Abstract A56: A dose-escalating phase 1b study assessing the safety, tolerability and efficacy of LY2780301 (a p70S6K/Akt inhibitor) in combination with gemcitabine in molecularly-selected patients with advanced or metastatic cancer

    Abstract A56: A dose-escalating phase 1b study assessing the safety, tolerability and efficacy of LY2780301 (a p70S6K/Akt inhibitor) in combination with gemcitabine in molecularly-... by ANGEVIN, ERIC, CASSIER, PHILIPPE, ITALIANO, ANTOINE, GONCALVES, ANTHONY, GAZZAH, ANAS, TERRET, CATHERINE, TOULMONDE, MAUD, GRAVIS, GWENAELLE, VARGA, ANDREA, PARLAVECCHIO, CEDRIC, SORIA, JEAN-CHARLES, LANOY, EMILIE, HOLLEBECQUE, ANTOINE

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: